Rafael Holdings, Inc. (NYSE:RFL) Short Interest Up 89.0% in July

Rafael Holdings, Inc. (NYSE:RFL) saw a significant growth in short interest in July. As of July 15th, there was short interest totaling 252,495 shares, a growth of 89.0% from the June 30th total of 133,570 shares. Currently, 0.7% of the shares of the stock are short sold. Based on an average trading volume of 317,195 shares, the short-interest ratio is currently 0.8 days.

Rafael Price Performance

Shares of RFL opened at $1.95 on Friday. The stock has a market capitalization of $101.40 million, a price-to-earnings ratio of -2.87 and a beta of 0.29. Rafael has a 1 year low of $1.12 and a 1 year high of $3.96. The business’s 50 day simple moving average is $2.23 and its 200-day simple moving average is $1.61.

Analyst Ratings Changes

Several analysts have commented on the stock. Weiss Ratings upgraded shares of Rafael from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 28th. Wall Street Zen upgraded Rafael to a “hold” rating in a research report on Saturday, July 25th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Rafael currently has an average rating of “Sell”.

Institutional Investors Weigh In On Rafael

A number of hedge funds have recently bought and sold shares of RFL. Geode Capital Management LLC lifted its position in Rafael by 72.9% during the second quarter. Geode Capital Management LLC now owns 451,139 shares of the company’s stock valued at $781,000 after purchasing an additional 190,179 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Rafael during the 2nd quarter valued at about $50,000. Cable Car Capital LP purchased a new stake in shares of Rafael during the 2nd quarter valued at about $173,000. Vanguard Group Inc. raised its position in shares of Rafael by 10.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,394,726 shares of the company’s stock valued at $1,897,000 after buying an additional 133,024 shares in the last quarter. Finally, Citadel Advisors LLC lifted its holdings in shares of Rafael by 132.3% in the 3rd quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock valued at $99,000 after acquiring an additional 41,335 shares during the last quarter. Hedge funds and other institutional investors own 11.30% of the company’s stock.

Rafael Company Profile

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.